mRNA vaccine designs for optimal adjuvanticity and delivery

References

• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–838. doi: 10.1038/s41573-021-00283-5
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi: 10.1038/s41591-021-01377-8
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi: 10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi: 10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–80. doi: 10.1016/j.cell.2021.01.007
   PubMed Web of Science ®Google Scholar
• Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron. Nature. 2022;603(7901):493–6. doi: 10.1038/s41586-022-04465-y
   PubMed Web of Science ®Google Scholar
• Liu C, Shi Q, Huang X, et al. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23(8):526–43. doi: 10.1038/s41568-023-00586-2
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–12. doi: 10.1038/s41586-020-2537-9
   PubMed Web of Science ®Google Scholar
• Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–50. doi: 10.1038/s41586-023-06063-y
   PubMed Web of Science ®Google Scholar
• Yang R, Deng Y, Huang B, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Sig Transduct Target Ther. 2021;6(1):213. doi: 10.1038/s41392-021-00634-z
   PubMed Web of Science ®Google Scholar
• Hassett KJ, Rajlic IL, Bahl K, et al. mRNA Vaccine Trafficking and Resulting Protein Expression After Intramuscular Administration. Mol Ther Nucleic Acids. doi: 10.1016/j.omtn.2023.102083
   Google Scholar
• Krauson AJ, Casimero FVC, Siddiquee Z, et al. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccin. 2023;8(1):141. doi: 10.1038/s41541-023-00742-7
   PubMedGoogle Scholar
• Mallapaty S, Callaway E, Kozlov M, et al. How COVID vaccines shaped 2021 in eight powerful charts. Nature. 2021;600(7890):580–3. doi: 10.1038/d41586-021-03686-x
   PubMed Web of Science ®Google Scholar
• Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993;23(7):1719–22. doi: 10.1002/eji.1830230749
   PubMed Web of Science ®Google Scholar
• Conry RM, LoBuglio AF, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995;55(7):1397–1400.
   PubMed Web of Science ®Google Scholar
• Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75. doi: 10.1016/j.immuni.2005.06.008
   PubMed Web of Science ®Google Scholar
• Wang J, Zhu H, Gan J, et al. Engineered mRNA delivery systems for biomedical applications. Adv Mater. n/a:2308029. doi: 10.1002/adma.202308029
   Google Scholar
• Rouf NZ, Biswas S, Tarannum N, et al. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biol. 2022;19(1):386–410. doi: 10.1080/15476286.2022.2055923
   PubMed Web of Science ®Google Scholar
• Alameh MG, Tombacz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877–92 e7. doi: 10.1016/j.immuni.2021.11.001
   PubMed Web of Science ®Google Scholar
• Li C, Lee A, Grigoryan L, et al. Mechanisms of innate and adaptive immunity to the pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022;23(4):543–55. doi: 10.1038/s41590-022-01163-9
   PubMed Web of Science ®Google Scholar
• Rosa SS, Prazeres DMF, Azevedo AM, et al. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine. 2021;39(16):2190–200. doi: 10.1016/j.vaccine.2021.03.038
   PubMed Web of Science ®Google Scholar
• Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–94. doi: 10.1038/s41578-021-00358-0
   PubMed Web of Science ®Google Scholar
• Uchida S, Yin Jerry Lau C, Oba M, et al. Polyplex designs for improving the stability and safety of RNA therapeutics. Adv Drug Deliv Rev. 2023;199:114972. doi: 10.1016/j.addr.2023.114972
   PubMed Web of Science ®Google Scholar
• Altmann DM, Boyton RJ. COVID-19 vaccination: the road ahead. Science. 2022;375(6585):1127–32. doi: 10.1126/science.abn1755
   PubMed Web of Science ®Google Scholar
• Callaway E. The next generation of coronavirus vaccines: a graphical guide. Nature. 2023;614(7946):22–5. doi: 10.1038/d41586-023-00220-z
   PubMedGoogle Scholar
• Barbier AJ, Jiang AY, Zhang P, et al. The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnol. 2022;40(6):840–54. doi: 10.1038/s41587-022-01294-2
   PubMed Web of Science ®Google Scholar
• Pulendran B, SA P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–75. doi: 10.1038/s41573-021-00163-y
   PubMed Web of Science ®Google Scholar
• Kobiyama K, Ishii KJ. Making innate sense of mRNA vaccine adjuvanticity. Nat Immunol. 2022;23(4):474–476. doi: 10.1038/s41590-022-01168-4
   PubMedGoogle Scholar
• Arunachalam PS, Scott MKD, Hagan T, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596(7872):410–6. doi: 10.1038/s41586-021-03791-x
   PubMed Web of Science ®Google Scholar
• Verbeke R, Hogan MJ, Lore K, et al. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55(11):1993–2005. doi: 10.1016/j.immuni.2022.10.014
   PubMed Web of Science ®Google Scholar
• Abbasi S, Uchida S. Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines. Pharmaceutics. 2021;13(5):644. doi: 10.3390/pharmaceutics13050644
   PubMedGoogle Scholar
• Schlosser E, Mueller M, Fischer S, et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine. 2008;26(13):1626–37. doi: 10.1016/j.vaccine.2008.01.030
   PubMed Web of Science ®Google Scholar
• Fischer NO, Rasley A, Corzett M, et al. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. J Am Chem Soc. 2013;135(6):2044–7. doi: 10.1021/ja3063293
   PubMed Web of Science ®Google Scholar
• Botos I, Liu L, Wang Y, et al. The toll-like receptor 3: dsRNA signaling complex. Biochim Biophys Acta. 2009;1789(9–10):667–74. doi: 10.1016/j.bbagrm.2009.06.005
   PubMedGoogle Scholar
• Tanji H, Ohto U, Shibata T, et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat Struct Mol Biol. 2015;22(2):109–15. doi: 10.1038/nsmb.2943
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Mikamo-Satoh E, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid–inducible gene-I and melanoma differentiation–associated gene 5. J Exp Med. 2008;205(7):1601–1610. doi: 10.1084/jem.20080091
   PubMed Web of Science ®Google Scholar
• Schlee M, Roth A, Hornung V, et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity. 2009;31(1):25–34. doi: 10.1016/j.immuni.2009.05.008
   PubMed Web of Science ®Google Scholar
• Nelson J, Sorensen EW, Mintri S, et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci Adv. 2020;6(26):eaaz6893. doi: 10.1126/sciadv.aaz6893
   PubMed Web of Science ®Google Scholar
• Schuberth-Wagner C, Ludwig J, Bruder AK, et al. A conserved histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2′O-Methylated self RNA. Immunity. 2015;43(1):41–51. doi: 10.1016/j.immuni.2015.06.015
   PubMed Web of Science ®Google Scholar
• Despic V, Jaffrey SR. mRNA ageing shapes the Cap2 methylome in mammalian mRNA. Nature. 2023;614(7947):358–366. doi: 10.1038/s41586-022-05668-z
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Murai R, Hagiwara H, et al. Preparation of eukaryotic mRNA having differently methylated adenosine at the 5′-terminus and the effect of the methyl group in translation. Nucleic Acids Symp Ser. 2009;53(1):129–130. doi: 10.1093/nass/nrp065
   Google Scholar
• Vlatkovic I, Ludwig J, Boros G, et al. Ribozyme assays to quantify the capping efficiency of in vitro-transcribed mRNA. Pharmaceutics. 2022;14(2):328. doi: 10.3390/pharmaceutics14020328
   PubMed Web of Science ®Google Scholar
• Moradian H, Roch T, Anthofer L, et al. Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages. Mol Ther Nucleic Acids. 2022;27:854–69. doi: 10.1016/j.omtn.2022.01.004
   PubMedGoogle Scholar
• Kariko K, Muramatsu H, Ludwig J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21):e142. doi: 10.1093/nar/gkr695
   PubMed Web of Science ®Google Scholar
• Triana-Alonso FJ, Dabrowski M, Wadzack J, et al. Self-coded 3′-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J Biol Chem. 1995;270(11):6298–6307. doi: 10.1074/jbc.270.11.6298
   PubMed Web of Science ®Google Scholar
• Gholamalipour Y, Karunanayake Mudiyanselage A, Martin CT. 3′ end additions by T7 RNA polymerase are RNA self-templated, distributive and diverse in character—RNA-Seq analyses. Nucleic Acids Res. 2018;46(18):9253–9263. doi: 10.1093/nar/gky796
   PubMed Web of Science ®Google Scholar
• Kobiyama K, Imai M, Jounai N, et al. Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain. bioRxiv. 2021:2021.03.04.433852. doi: 10.1101/2021.03.04.433852
   Google Scholar
• Anderson BR, Muramatsu H, Jha BK, et al. Nucleoside modifications in RNA limit activation of 2’-5’-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 2011;39(21):9329–38. doi: 10.1093/nar/gkr586
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38(17):5884–92. doi: 10.1093/nar/gkq347
   PubMed Web of Science ®Google Scholar
• Inagaki M, Abe N, Li Z, et al. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat Commun. 2023;14(1):2657. doi: 10.1038/s41467-023-38244-8
   PubMedGoogle Scholar
• Dousis A, Ravichandran K, Hobert EM, et al. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nature Biotechnol. 2023;41(4):560–8. doi: 10.1038/s41587-022-01525-6
   PubMedGoogle Scholar
• Ndeupen S, Qin Z, Jacobsen S, et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12):103479. doi: 10.1016/j.isci.2021.103479
   PubMed Web of Science ®Google Scholar
• Miao L, Li L, Huang Y, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nature Biotechnol. 2019;37(10):1174–85. doi: 10.1038/s41587-019-0247-3
   PubMed Web of Science ®Google Scholar
• Zhang H, You X, Wang X, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci USA. 2021;118(6):e2005191118. doi: 10.1073/pnas.2005191118
   PubMed Web of Science ®Google Scholar
• Han X, Alameh MG, Butowska K, et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat Nanotech. 2023;18(9):1105–14. doi: 10.1038/s41565-023-01404-4
   PubMedGoogle Scholar
• Sharp FA, Ruane D, Claass B, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci, USA. 2009;106(3):870–875. doi: 10.1073/pnas.0804897106
   PubMed Web of Science ®Google Scholar
• Forster Iii J, Nandi D, Kulkarni A. mRNA-carrying lipid nanoparticles that induce lysosomal rupture activate NLRP3 inflammasome and reduce mRNA transfection efficiency. Biomater Sci. 2022;10(19):5566–82. doi: 10.1039/D2BM00883A
   PubMedGoogle Scholar
• Sokal A, Bastard P, Chappert P, et al. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. J Exp Med. 2023;220(1):220. doi: 10.1084/jem.20220258
   Google Scholar
• Ndeupen S, Bouteau A, Herbst C, et al. Langerhans cells and cDc1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses. PLoS Pathog. 2022;18(1):e1010255. doi: 10.1371/journal.ppat.1010255
   PubMedGoogle Scholar
• Liang F, Lindgren G, Lin A, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25(12):2635–47. doi: 10.1016/j.ymthe.2017.08.006
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Tong AJ, Himmels P, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532–42. doi: 10.1038/s41590-022-01160-y
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. doi: 10.1038/nature18300
   PubMed Web of Science ®Google Scholar
• Krienke C, Kolb L, Diken E, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145–53. doi: 10.1126/science.aay3638
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19(5):990–9. doi: 10.1038/mt.2010.289
   PubMed Web of Science ®Google Scholar
• Kreiter S, Diken M, Selmi A, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 2011;71(19):6132–42. doi: 10.1158/0008-5472.can-11-0291
   PubMed Web of Science ®Google Scholar
• Zhuang X, Chen L, Yang S, et al. R848 adjuvant laden with self-assembled nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 in mice. Front Immunol. 2022;13:836274. doi: 10.3389/fimmu.2022.836274
   PubMedGoogle Scholar
• Fan N, Chen K, Zhu R, et al. Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. Sci Adv. 2022;8(51):eabq3500. doi: 10.1126/sciadv.abq3500
   PubMed Web of Science ®Google Scholar
• Yang J, Arya S, Lung P, et al. Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant. Nanoscale. 2019;11(45):21782–9. doi: 10.1039/C9NR05475H
   PubMedGoogle Scholar
• Islam MA, Rice J, Reesor E, et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021;266:120431. doi: 10.1016/j.biomaterials.2020.120431
   PubMed Web of Science ®Google Scholar
• Gu Y, Yang J, He C, et al. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases. Signal Transduct Target Ther. 2023;8(1):273. doi: 10.1038/s41392-023-01479-4
   PubMed Web of Science ®Google Scholar
• Verbeke R, Lentacker I, Breckpot K, et al. Broadening the message: a Nanovaccine Co-loaded with Messenger RNA and alpha-GalCer induces antitumor immunity through conventional and natural killer T cells. ACS Nano. 2019;13:1655–1669. doi: 10.1021/acsnano.8b07660
   PubMedGoogle Scholar
• Ganley M, Holz LE, Minnell JJ, et al. mRNA vaccine against malaria tailored for liver-resident memory T cells. Nat Immunol. 2023;24(9):1487–98. doi: 10.1038/s41590-023-01562-6
   PubMedGoogle Scholar
• Guevara ML, Jilesen Z, Stojdl D, et al. Codelivery of mRNA with α-Galactosylceramide Using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration. ACS Omega. 2019;4(8):13015–13026. doi: 10.1021/acsomega.9b00489
   PubMed Web of Science ®Google Scholar
• Verbeke R, Lentacker I, Wayteck L, et al. Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA. J Control Release. 2017;266:287–300. doi: 10.1016/j.jconrel.2017.09.041
   PubMed Web of Science ®Google Scholar
• Pan L, Zhang L, Deng W, et al. Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses. J Control Release. 2023;357:133–48. doi: 10.1016/j.jconrel.2023.03.041
   PubMed Web of Science ®Google Scholar
• Li B, Jiang AY, Raji I, et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nat Biomed Eng. 2023. doi: 10.1038/s41551-023-01082-6
   Web of Science ®Google Scholar
• Oyama R, Ishigame H, Tanaka H, et al. An ionizable lipid material with a vitamin E scaffold as an mRNA vaccine platform for efficient cytotoxic T cell responses. ACS Nano. 2023;17(19):18758–74. doi: 10.1021/acsnano.3c02251
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan J, Hou X, et al. STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2. Nano Lett. 2023;23(7):2593–600. doi: 10.1021/acs.nanolett.2c04883
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Xu Z, et al. mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma. Mol Ther. 2018;26(2):420–34. doi: 10.1016/j.ymthe.2017.11.009
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34(1):1–15. doi: 10.1097/CJI.0b013e3181f7dbe8
   PubMed Web of Science ®Google Scholar
• Son S, Nam J, Zenkov I, et al. Sugar-Nanocapsules Imprinted with microbial molecular patterns for mRNA vaccination. Nano Lett. 2020;20(3):1499–509. doi: 10.1021/acs.nanolett.9b03483
   PubMed Web of Science ®Google Scholar
• Duan X, Zhang Y, Guo M, et al. Sodium alginate coating simultaneously increases the biosafety and immunotherapeutic activity of the cationic mRNA nanovaccine. Acta Pharm Sin B. 2023;13(3):942–54. doi: 10.1016/j.apsb.2022.08.015
   PubMed Web of Science ®Google Scholar
• Huang P, Jiang L, Pan H, et al. An integrated polymeric mRNA vaccine without inflammation side effects for cellular immunity mediated cancer therapy. Adv Mater. 2023;35(3):e2207471. doi: 10.1002/adma.202207471
   PubMed Web of Science ®Google Scholar
• Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012;72(7):1661–71. doi: 10.1158/0008-5472.can-11-2957
   PubMed Web of Science ®Google Scholar
• Tse SW, McKinney K, Walker W, et al. mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response. Mol Ther. 2021;29(7):2227–2238. doi: 10.1016/j.ymthe.2021.03.002
   PubMed Web of Science ®Google Scholar
• Blakney AK, McKay PF, Bouton CR, et al. Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA. Mol Ther. 2021;29:1174–1185. doi: 10.1016/j.ymthe.2020.11.011
   PubMed Web of Science ®Google Scholar
• Beissert T, Koste L, Perkovic M, et al. Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins. Hum Gene Ther. 2017;28(12):1138–46. doi: 10.1089/hum.2017.121
   PubMed Web of Science ®Google Scholar
• Uchida S, Yoshinaga N, Yanagihara K, et al. Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly a sequences for effective vaccination. Biomaterials. 2018;150:162–170. doi: 10.1016/j.biomaterials.2017.09.033
   PubMed Web of Science ®Google Scholar
• Tockary TA, Abbasi S, Matsui-Masai M, et al. Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment. Proc Natl Acad Sci, USA. 2023;120(29):e2214320120. doi: 10.1073/pnas.2214320120
   PubMedGoogle Scholar
• Hassett KJ, Benenato KE, Jacquinet E, et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019;15:1–11. doi: 10.1016/j.omtn.2019.01.013
   PubMedGoogle Scholar
• Blakney AK, McKay PF, Hu K, et al. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. J Control Release. 2021;338:201–10. doi: 10.1016/j.jconrel.2021.08.029
   PubMed Web of Science ®Google Scholar
• Sittplangkoon C, Alameh MG, Weissman D, et al. mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model. Front Immunol. 2022;13:983000. doi: 10.3389/fimmu.2022.983000
   PubMed Web of Science ®Google Scholar
• Kumar R, Santa Chalarca CF, Bockman MR, et al. Polymeric delivery of therapeutic nucleic acids. Chem Rev. 2021;121(18):11527–652. doi: 10.1021/acs.chemrev.0c00997
   PubMed Web of Science ®Google Scholar
• Kallen KJ, Heidenreich R, Schnee M, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines. Hum Vaccin Immunother. 2013;9(10):2263–76. doi: 10.4161/hv.25181
   PubMed Web of Science ®Google Scholar
• Wegmann F, Gartlan KH, Harandi AM, et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nature Biotechnol. 2012;30(9):883–8. doi: 10.1038/nbt.2344
   PubMed Web of Science ®Google Scholar
• Gong T, Liu L, Jiang W, et al. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95–112. doi: 10.1038/s41577-019-0215-7
   PubMed Web of Science ®Google Scholar
• Vogel AB, Lambert L, Kinnear E, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26(2):446–55. doi: 10.1016/j.ymthe.2017.11.017
   PubMed Web of Science ®Google Scholar
• Hồ N, Hughes S, Tạ V, et al. Safety and immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine. Res Square. 2023. doi: 10.21203/rs.3.rs-3329097/v1
   Google Scholar
• Zhong Z, Portela Catani JP, Mc Cafferty S, et al. Immunogenicity and protection efficacy of a naked self-replicating mRNA-based zika virus vaccine. Vaccines (Basel). 2019;7(3):96. doi: 10.3390/vaccines7030096
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Stirling DC, Wang Z, et al. Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines. Mol Ther Nucleic Acids. 2023;31:29–42. doi: 10.1016/j.omtn.2022.11.024
   PubMedGoogle Scholar
• Yoshinaga N, Uchida S, Naito M, et al. Induced packaging of mRNA into polyplex micelles by regulated hybridization with a small number of cholesteryl RNA oligonucleotides directed enhanced in vivo transfection. Biomaterials. 2019;197:255–67. doi: 10.1016/j.biomaterials.2019.01.023
   PubMed Web of Science ®Google Scholar
• Yoshinaga N, Cho E, Koji K, et al. Bundling mRNA strands to prepare Nano-assemblies with enhanced stability towards RNase for in vivo delivery. Angew Chem Int Ed. 2019;58(33):11360–3. doi: 10.1002/anie.201905203
   PubMed Web of Science ®Google Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326–35. doi: 10.1021/acs.nanolett.6b03329
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–88. doi: 10.1084/jem.20171450
   PubMed Web of Science ®Google Scholar
• Melamed JR, Hajj KA, Chaudhary N, et al. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. J Control Release. 2021;341:206–214. doi: 10.1016/j.jconrel.2021.11.022
   PubMed Web of Science ®Google Scholar
• Bernard M-C, Bazin E, Petiot N, et al. The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system. Mol Ther Nucleic Acids. 2023;32:794–806. doi: 10.1016/j.omtn.2023.05.004
   PubMedGoogle Scholar
• Gebre MS, Rauch S, Roth N, et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2022;601(7893):410–4. doi: 10.1038/s41586-021-04231-6
   PubMed Web of Science ®Google Scholar
• Pollard C, Rejman J, De Haes W, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251–9. doi: 10.1038/mt.2012.202
   PubMed Web of Science ®Google Scholar
• De Beuckelaer A, Pollard C, Van Lint S, et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol Ther. 2016;24(11):2012–20. doi: 10.1038/mt.2016.161
   PubMed Web of Science ®Google Scholar
• Broos K, Van der Jeught K, Puttemans J, et al. Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids. 2016;5:e326. doi: 10.1038/mtna.2016.38
   PubMedGoogle Scholar
• Van Hoecke L, Roose K, Ballegeer M, et al. The opposing effect of type I IFN on the T cell response by non-modified mRNA-lipoplex vaccines is determined by the route of administration. Mol Ther Nucleic Acids. 2020;22:373–81. doi: 10.1016/j.omtn.2020.09.004
   PubMedGoogle Scholar
• Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015;15(4):231–42. doi: 10.1038/nri3806
   PubMed Web of Science ®Google Scholar
• Qin Z, Bouteau A, Herbst C, et al. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. PLoS Pathog. 2022;18(9):e1010830. doi: 10.1371/journal.ppat.1010830
   PubMed Web of Science ®Google Scholar
• Hall VG, Ferreira VH, Wood H, et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022;23(3):380–5. doi: 10.1038/s41590-021-01126-6
   PubMed Web of Science ®Google Scholar
• Thomas SN, Rohner NA, Edwards EE. Implications of Lymphatic Transport to Lymph Nodes in immunity and immunotherapy. Annu Rev Biomed Eng. 2016;18(1):207–233. doi: 10.1146/annurev-bioeng-101515-014413
   PubMedGoogle Scholar
• Boettler T, Csernalabics B, Salie H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol. 2022;77(3):653–9. doi: 10.1016/j.jhep.2022.03.040
   PubMed Web of Science ®Google Scholar
• Bos JD, Kapsenberg ML. The skin immune system: progress in cutaneous biology. Immunol Today. 1993;14(2):75–8. doi: 10.1016/0167-5699(93)90062-P
   PubMedGoogle Scholar
• Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection. Nature Biotechnol. 2012;30(12):1210–6. doi: 10.1038/nbt.2436
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–20. doi: 10.1016/s0140-6736(17)31665-3
   PubMed Web of Science ®Google Scholar
• Roozen GVT, Prins MLM, van Binnendijk R, et al. Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv. 2021. doi: 10.1101/2021.07.27.21261116
   Google Scholar
• Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population. Vaccines (Basel). 2021;9(12):1375. doi: 10.3390/vaccines9121375
   PubMed Web of Science ®Google Scholar
• Kübler H, Scheel B, Gnad-Vogt U, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer. 2015;3(1):26. doi: 10.1186/s40425-015-0068-y
   PubMedGoogle Scholar
• Golombek S, Pilz M, Steinle H, et al. Intradermal delivery of synthetic mRNA using hollow microneedles for efficient and Rapid Production of Exogenous Proteins in skin. Mol Ther Nucleic Acids. 2018;11:382–92. doi: 10.1016/j.omtn.2018.03.005
   PubMedGoogle Scholar
• Peracchia MT, Fattal E, Desmaele D, et al. Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release. 1999;60(1):121–128. doi: 10.1016/s0168-3659(99)00063-2
   PubMed Web of Science ®Google Scholar
• Liu S, Wang X, Yu X, et al. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes. J Am Chem Soc. 2021;143(50):21321–30. doi: 10.1021/jacs.1c09822
   PubMed Web of Science ®Google Scholar
• Chen P, He X, Hu Y, et al. Spleen-targeted mRNA delivery by amphiphilic carbon dots for tumor immunotherapy. ACS Appl Mater Interfaces. 2023;15(16):19937–50. doi: 10.1021/acsami.3c00494
   PubMed Web of Science ®Google Scholar
• Perche F, Benvegnu T, Berchel M, et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine. 2011;7(4):445–53. doi: 10.1016/j.nano.2010.12.010
   PubMed Web of Science ®Google Scholar
• Van der Jeught K, De Koker S, Bialkowski L, et al. Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety. ACS Nano. 2018;12(10):9815–9829. doi: 10.1021/acsnano.8b00966
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Ward RW. Mucosal vaccines — fortifying the frontiers. Nat Rev Immunol. 2022;22(4):236–250. doi: 10.1038/s41577-021-00583-2
   PubMed Web of Science ®Google Scholar
• Phua KK, Staats HF, Leong KW, et al. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep. 2014;4(1):5128. doi: 10.1038/srep05128
   PubMedGoogle Scholar
• Mai Y, Guo J, Zhao Y, et al. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell Immunol. 2020;354:104143. doi: 10.1016/j.cellimm.2020.104143
   PubMed Web of Science ®Google Scholar
• Li M, Zhao M, Fu Y, et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release. 2016;228:9–19. doi: 10.1016/j.jconrel.2016.02.043
   PubMed Web of Science ®Google Scholar
• Li M, Li Y, Peng K, et al. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomater. 2017;64:237–48. doi: 10.1016/j.actbio.2017.10.019
   PubMed Web of Science ®Google Scholar
• Sahni N, Cheng Y, Middaugh CR, et al. Vaccine Delivery. Drug Delivery. 2016;623–654.
   Google Scholar
• Cook IF. Subcutaneous vaccine administration – an outmoded practice. Hum Vaccin Immunother. 2021;17(5):1329–1341. doi: 10.1080/21645515.2020.1814094
   PubMed Web of Science ®Google Scholar
• Lee J, Kim D, Byun J, et al. In vivo fate and intracellular trafficking of vaccine delivery systems. Adv Drug Deliv Rev. 2022;186:114325. doi: 10.1016/j.addr.2022.114325
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang Q, Sun X. Lymph node targeting strategies to improve vaccination efficacy. J Control Release. 2017;267:47–56. doi: 10.1016/j.jconrel.2017.08.009
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sato Y, Yamada Y, et al. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. Adv Drug Deliv Rev. 2022;188:114417. doi: 10.1016/j.addr.2022.114417
   PubMed Web of Science ®Google Scholar
• Nakamura T, Harashima H. Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy. Adv Drug Deliv Rev. 2020;167:78–88. doi: 10.1016/j.addr.2020.06.003
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Kaminskas LM, Porter CJ. From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14(11):781–803. doi: 10.1038/nrd4608
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38(5):1404–13. doi: 10.1002/eji.200737984
   PubMed Web of Science ®Google Scholar
• Ryan GM, Kaminskas LM, Porter CJ. Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. J Control Release. 2014;193:241–256. doi: 10.1016/j.jconrel.2014.04.051
   PubMed Web of Science ®Google Scholar
• Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50(1–2):3–20. doi: 10.1016/s0169-409x(01)00150-8
   PubMed Web of Science ®Google Scholar
• Engin AB, Nikitovic D, Neagu M, et al. Mechanistic understanding of nanoparticles’ interactions with extracellular matrix: the cell and immune system. Part Fibre Toxicol. 2017;14(1):22. doi: 10.1186/s12989-017-0199-z
   PubMedGoogle Scholar
• Verma A, Stellacci F. Effect of surface properties on nanoparticle–cell interactions. Small. 2010;6(1):12–21. doi: 10.1002/smll.200901158
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Zhu D, et al. Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies. Acta Pharm Sin B. 2021;11(4):886–902. doi: 10.1016/j.apsb.2021.03.007
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm Res. 1997;14(10):1479–84. doi: 10.1023/a:1012145410859
   PubMed Web of Science ®Google Scholar
• Ding Y, Li Z, Jaklenec A, et al. Vaccine delivery systems toward lymph nodes. Adv Drug Deliv Rev. 2021;179:113914. doi: 10.1016/j.addr.2021.113914
   PubMed Web of Science ®Google Scholar
• McCright J, Skeen C, Yarmovsky J, et al. Nanoparticles with dense poly(ethylene glycol) coatings with near neutral charge are maximally transported across lymphatics and to the lymph nodes. Acta Biomater. 2022;145:146–58. doi: 10.1016/j.actbio.2022.03.054
   PubMed Web of Science ®Google Scholar
• Moghimi SM. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials. 2006;27(1):136–44. doi: 10.1016/j.biomaterials.2005.05.082
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Ma Y, Wang C, et al. Pegylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution. J Control Release. 2012;159(1):135–42. doi: 10.1016/j.jconrel.2011.12.017
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, et al. Pegylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51. doi: 10.1016/j.addr.2015.09.012
   PubMed Web of Science ®Google Scholar
• Nahar UJ, Toth I, Skwarczynski M. Mannose in vaccine delivery. J Control Release. 2022;351:284–300. doi: 10.1016/j.jconrel.2022.09.038
   PubMedGoogle Scholar
• Cruz LJ, Rosalia RA, Kleinovink JW, et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release. 2014;192:209–218. doi: 10.1016/j.jconrel.2014.07.040
   PubMed Web of Science ®Google Scholar
• Wilson NS, El-Sukkari D, Belz GT, et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood. 2003;102(6):2187–94. doi: 10.1182/blood-2003-02-0513
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031–40. doi: 10.1158/0008-5472.can-10-0699
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6. doi: 10.1038/nature23003
   PubMed Web of Science ®Google Scholar
• Lindsay KE, Bhosle SM, Zurla C, et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging. Nat Biomed Eng. 2019;3(5):371–380. doi: 10.1038/s41551-019-0378-3
   PubMed Web of Science ®Google Scholar
• Roltgen K, Nielsen SCA, Silva O, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185(6):1025–1040.e14. doi: 10.1016/j.cell.2022.01.018
   PubMed Web of Science ®Google Scholar
• Takanashi A, Pouton CW, Al-Wassiti H. Delivery and expression of mRNA in the secondary lymphoid organs drive immune responses to lipid nanoparticle-mRNA vaccines after intramuscular injection. Mol Pharm. 2023;20(8):3876–85. doi: 10.1021/acs.molpharmaceut.2c01024
   PubMedGoogle Scholar
• Hassett KJ, Higgins J, Woods A, et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Control Release. 2021;335:237–46. doi: 10.1016/j.jconrel.2021.05.021
   PubMed Web of Science ®Google Scholar
• Shi Y, Huang J, Liu Y, et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti–SARS-CoV-2 humoral and cellular immune responses. Sci Adv. 2022;8(47):eabo1827. doi: 10.1126/sciadv.abo1827
   PubMedGoogle Scholar
• Shi Y, Lu Y, Qin B, et al. Antigen transfer from non-APCs to APCs impacts the efficacy and safety of protein- and mRNA- based vaccines. Nano Today. 2021;41:41. doi: 10.1016/j.nantod.2021.101326
   Google Scholar
• Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol. 1997;9(12):1897–1906. doi: 10.1093/intimm/9.12.1897
   PubMedGoogle Scholar
• Willis E, Pardi N, Parkhouse K, et al. Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci Transl Med. 2020;12(525):eaav5701. doi: 10.1126/scitranslmed.aav5701
   PubMedGoogle Scholar
• Amano T, Yu H, Amano M, et al. Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity. iScience. 2023;26(4):106335. doi: 10.1016/j.isci.2023.106335
   PubMedGoogle Scholar
• Kimura T, Leal JM, Simpson A, et al. A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation. Mol Ther. 2023;31(8):2360–75. doi: 10.1016/j.ymthe.2023.06.017
   PubMedGoogle Scholar
• Chen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8 + T cell response. Proc Natl Acad Sci U S A. 2022;119(34):e2207841119. doi: 10.1073/pnas.2207841119
   PubMedGoogle Scholar
• Di J, Du Z, Wu K, et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm Res. 2022;39(1):105–14. doi: 10.1007/s11095-022-03166-5
   PubMed Web of Science ®Google Scholar
• Akinc A, Querbes W, De S, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357–64. doi: 10.1038/mt.2010.85
   PubMed Web of Science ®Google Scholar
• Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci USA. 2021;118(52):e2109256118. doi: 10.1073/pnas.2109256118
   PubMedGoogle Scholar
• Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin. 2011;7(8):811–27. doi: 10.4161/hv.7.8.16274
   PubMed Web of Science ®Google Scholar
• Sophonmanee R, Ongarj J, Seeyankem B, et al. T-Cell responses induced by an intradermal BNT162b2 mRNA vaccine booster following primary vaccination with inactivated SARS-CoV-2 vaccine. Vaccines (Basel). 2022;10(9):1494. doi: 10.3390/vaccines10091494
   PubMedGoogle Scholar
• Blakney AK, Zhu Y, McKay PF, et al. Big is beautiful: enhanced saRNA delivery and immunogenicity by a higher molecular weight, Bioreducible, cationic polymer. ACS Nano. 2020;14(5):5711–27. doi: 10.1021/acsnano.0c00326
   PubMed Web of Science ®Google Scholar
• Anderluzzi G, Lou G, Woods S, et al. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency. J Control Release. 2022;342:388–99. doi: 10.1016/j.jconrel.2021.12.008
   PubMed Web of Science ®Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–208. doi: 10.1016/j.vaccine.2008.03.095
   PubMed Web of Science ®Google Scholar
• Shimizu S, Tanaka R, Itoh E, et al. Performance and usability evaluation of novel intradermal injection device Immucise™ and reanalysis of intradermal administration trials of influenza vaccine for the elderly. Vaccine. 2022;40(6):873–879. doi: 10.1016/j.vaccine.2021.12.061
   PubMedGoogle Scholar
• Vander Straeten A, Sarmadi M, Daristotle JL, et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nature Biotechnol. 2023;42(3):510–517. doi: 10.1038/s41587-023-01774-z
   PubMed Web of Science ®Google Scholar
• Baharom F, Ramirez-Valdez RA, Tobin KKS, et al. Intravenous nanoparticle vaccination generates stem-like TCF1(+) neoantigen-specific CD8(+) T cells. Nat Immunol. 2021;22(1):41–52. doi: 10.1038/s41590-020-00810-3
   PubMed Web of Science ®Google Scholar
• Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. Sci Immunol. 2019;4(33). doi: 10.1126/sciimmunol.aau6085
   PubMed Web of Science ®Google Scholar
• Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165–70. doi: 10.1038/nbt1340
   PubMed Web of Science ®Google Scholar
• Shetty S, Lalor PF, Adams DH. Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol. 2018;15(9):555–567. doi: 10.1038/s41575-018-0020-y
   PubMed Web of Science ®Google Scholar
• Jacobs F, Wisse E, De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am J Pathol. 2010;176(1):14–21. doi: 10.2353/ajpath.2010.090136
   PubMed Web of Science ®Google Scholar
• Walkey CD, Olsen JB, Guo H, et al. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc. 2012;134(4):2139–2147. doi: 10.1021/ja2084338
   PubMed Web of Science ®Google Scholar
• Tsoi KM, MacParland SA, Ma XZ, et al. Mechanism of hard-nanomaterial clearance by the liver. Nature Mater. 2016;15(11):1212–21. doi: 10.1038/nmat4718
   PubMed Web of Science ®Google Scholar
• Pombo Garcia K, Zarschler K, Barbaro L, et al. Zwitterionic-coated “stealth” nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small. 2014;10(13):2516–2529. doi: 10.1002/smll.201303540
   PubMed Web of Science ®Google Scholar
• Dirisala A, Uchida S, Toh K, et al. Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines. Sci Adv. 2020;6(26):eabb8133. doi: 10.1126/sciadv.abb8133
   PubMed Web of Science ®Google Scholar
• Cataldi M, Vigliotti C, Mosca T, et al. Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes. Int J Mol Sci. 2017;18(6):1249. doi: 10.3390/ijms18061249
   PubMed Web of Science ®Google Scholar
• Kutscher HL, Chao P, Deshmukh M, et al. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release. 2010;143(1):31–7. doi: 10.1016/j.jconrel.2009.12.019
   PubMed Web of Science ®Google Scholar
• Pektor S, Hilscher L, Walzer KC, et al. In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI Res. 2018;8(1):80. doi: 10.1186/s13550-018-0435-z
   PubMedGoogle Scholar
• Cheng Q, Wei T, Farbiak L, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–cas gene editing. Nat Nanotech. 2020;15(4):313–320. doi: 10.1038/s41565-020-0669-6
   PubMed Web of Science ®Google Scholar
• Tang X, Zhang J, Sui D, et al. Simultaneous dendritic cells targeting and effective endosomal escape enhance sialic acid-modified mRNA vaccine efficacy and reduce side effects. J Control Release. 2023;364:529–45. doi: 10.1016/j.jconrel.2023.11.008
   PubMedGoogle Scholar
• Lamichhane A, Azegamia T, Kiyonoa H. The mucosal immune system for vaccine development. Vaccine. 2014;32(49):6711–23. doi: 10.1016/j.vaccine.2014.08.089
   PubMed Web of Science ®Google Scholar
• Mettelman RC, Allen EK, Thomas PG. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity. 2022;55(5):749–80. doi: 10.1016/j.immuni.2022.04.013
   PubMed Web of Science ®Google Scholar
• Huang M, Zhang M, Zhu H, et al. Mucosal vaccine delivery: a focus on the breakthrough of specific barriers. Acta Pharm Sin B. 2022;12(9):3456–74. doi: 10.1016/j.apsb.2022.07.002
   PubMed Web of Science ®Google Scholar
• Lijek RS, Luque SL, Liu Q, et al. Protection from the acquisition of staphylococcus aureus nasal carriage by cross-reactive antibody to a pneumococcal dehydrogenase. Proc Natl Acad Sci USA. 2012;109(34):13823–8. doi: 10.1073/pnas.1208075109
   PubMedGoogle Scholar
• Jang YH, Byun YH, Lee YJ, et al. Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J Virol. 2012;86(10):5953–8. doi: 10.1128/JVI.07149-11
   PubMed Web of Science ®Google Scholar
• Kraehenbuhl JP, Neutra MR. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol Rev. 1992;72(4):853–79. doi: 10.1152/physrev.1992.72.4.853
   PubMedGoogle Scholar
• Rhee JH. Current and new approaches for mucosal vaccine delivery. Mucosal Vaccines. 2020;325–356.
   Google Scholar
• Boyaka PN. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J Immunol. 2017;199(1):9–16. doi: 10.4049/jimmunol.1601775
   PubMed Web of Science ®Google Scholar
• van Splunter M, van Hoffen E, Floris-Vollenbroek EG, et al. Oral cholera vaccination promotes homing of IgA(+) memory B cells to the large intestine and the respiratory tract. Mucosal Immunol. 2018;11(4):1254–1264. doi: 10.1038/s41385-018-0006-7
   PubMed Web of Science ®Google Scholar
• Li M, Wang Y, Sun Y, et al. Mucosal vaccines: Strategies and challenges. Immunol Lett. 2020;217:116–25. doi: 10.1016/j.imlet.2019.10.013
   PubMed Web of Science ®Google Scholar
• Suberi A, Grun MK, Mao T, et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci Transl Med. 2023;15(709):eabq0603. doi: 10.1126/scitranslmed.abq0603
   PubMedGoogle Scholar
• Uchida S, Itaka K, Chen Q, et al. Pegylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol Ther. 2012;20(6):1196–203. doi: 10.1038/mt.2012.20
   PubMed Web of Science ®Google Scholar
• Cabral H, Li J, Miyata K, et al. Controlling the biodistribution and clearance of nanomedicines. Nat Rev Bioeng. 2023;2(3):214–232. doi: 10.1038/s44222-023-00138-1
   Google Scholar
• Rief W. Fear of adverse effects and COVID-19 vaccine hesitancy: recommendations of the treatment expectation expert group. JAMA Health Forum. 2021;2(4):e210804–e. doi: 10.1001/jamahealthforum.2021.0804
   PubMedGoogle Scholar
• Debes AK, Xiao S, Colantuoni E, et al. Association of vaccine type and prior SARS-CoV-2 infection with symptoms and antibody measurements following vaccination among health care workers. JAMA Intern Med. 2021;181(12):1660–2. doi: 10.1001/jamainternmed.2021.4580
   PubMed Web of Science ®Google Scholar
• Bauernfeind S, Salzberger B, Hitzenbichler F, et al. Association between reactogenicity and immunogenicity after vaccination with BNT162b2. Vaccines (Basel). 2021;9(10):1089. doi: 10.3390/vaccines9101089
   PubMed Web of Science ®Google Scholar
• Oda Y, Kumagai Y, Kanai M, et al. Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty®. medRxiv. 2023. doi: 10.1101/2023.07.13.23292597
   Google Scholar
• Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728–1744.e16. doi: 10.1016/j.cell.2022.03.044
   PubMed Web of Science ®Google Scholar
• Tam HH, Melo MB, Kang M, et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci USA. 2016;113(43):E6639–E48. doi: 10.1073/pnas.1606050113
   PubMed Web of Science ®Google Scholar
• Cirelli KM, Carnathan DG, Nogal B, et al. Slow Delivery Immunization Enhances HIV Neutralizing Antibody and germinal center responses via modulation of Immunodominance. Cell. 2019;177(5):1153–1171.e28. doi: 10.1016/j.cell.2019.04.012
   PubMed Web of Science ®Google Scholar
• Chen R, Zhang H, Yan J, et al. Scaffold-mediated delivery for non-viral mRNA vaccines. Gene Ther. 2018;25(8):556–67. doi: 10.1038/s41434-018-0040-9
   PubMed Web of Science ®Google Scholar
• Yin Y, Li X, Ma H, et al. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 2021;21(5):2224–31. doi: 10.1021/acs.nanolett.0c05039
   PubMed Web of Science ®Google Scholar
• Hoffmann MAG, Yang Z, Huey-Tubman KE, et al. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell. 2023;186(11):2380–2391.e9. doi: 10.1016/j.cell.2023.04.024
   PubMedGoogle Scholar